Skip to main content

Table 1 Patient cohorts and characteristics

From: Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy

 Cohort 1TCGA
No. of patients%No. of patients%
No. of patients55452
Sex
 Male3767.329064.2
 Female1832.716235.8
Age median (range)70 (32–84)61 (29–90)
Stage
 12443.622148.9
 235.5449.7
 31425.511625.7
 41425.56915.3
 NA20.4
Primary tumor
 12647.322750.2
 247.35612.4
 32443.616436.3
 411.851.1
N
 04683.620344.9
 1/2712.7112.4
 X23.623852.7
M
 04276.437783.4
 11323.66815.0
 X71.5
G
 1814.5102.2
 23869.118841.6
 3/4916.425155.5
 X10.2
 NA20.4
Median follow-up time [years] (range)2.9 (0–10.1)3.5 (0–12.4)
Overall survivala [years]
 Deceased2850.914532.1
 Alive2647.330767.9
  1. Abbreviations: N regional lymph nodes, M distant metastasis, G grading, NA not available
  2. aInformation on overall survival was not available for all patients